Design Therapeutics, Inc. Common Stock
DSGN US25056L1035
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -48% | -51% | -73% | 143% | 8% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| William Arsani O |
5.25 USD |
345,000 Sold |
1,811,250 USD |
13/08/2025 | 13/08/2025 |
| William Arsani O |
5.25 USD |
217,627 Sold |
1,142,542 USD |
13/08/2025 | 13/08/2025 |
| Prasad Deepa O |
6.27 USD |
3,806 Sold |
23,864 USD |
18/12/2024 | 18/12/2024 |
| William Arsani O |
4.25 USD |
814,874 Sold |
3,463,215 USD |
09/08/2024 | 09/08/2024 |
| Schmid John P. O |
3.74 USD |
17,809 Bought |
66,606 USD |
22/03/2024 | 25/03/2024 |
| Berger Heather A. O |
3.74 USD |
1,300 Bought |
4,866 USD |
25/03/2024 | 25/03/2024 |
| Schmid John P. O |
3.62 USD |
9,156 Bought |
33,133 USD |
22/03/2024 | 22/03/2024 |